BIOMAT Database Logo BIOMAT Database Logo

Autologous bone marrow transplantation for patients with acute myelogenous leukemia in complete remission. 1987

G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Institute of Hematology, University La Sapienza, Rome, Italy.

UI MeSH Term Description Entries
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000677 Amsacrine An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent. m-AMSA,AMSA,AMSA P-D,Amsacrina,Amsidine,Amsidyl,Cain's Acridine,NSC-141549,NSC-156303,NSC-249992,SN-11841,SN11841,meta-AMSA,AMSA P D,AMSA PD,Cain Acridine,Cains Acridine,NSC 141549,NSC 156303,NSC 249992,NSC141549,NSC156303,NSC249992,SN 11841,meta AMSA

Related Publications

G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
March 1996, Leukemia,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Autologous bone marrow transplantation in acute myelogenous leukemia.
November 1992, Leukemia,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Autologous bone marrow transplantation for acute leukemia in remission.
March 1987, British journal of haematology,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
January 1990, Bone marrow transplantation,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Autologous bone marrow transplantation for patients with advanced chronic myelogenous leukemia.
December 1997, International journal of hematology,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Autologous bone marrow transplantation in acute myeloid leukemia in relapse or in complete remission.
November 1982, Cancer treatment reports,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia.
June 1997, Blood reviews,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Bone marrow transplantation for children with acute myelogenous leukaemia in the first complete remission.
February 2000, European journal of cancer (Oxford, England : 1990),
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia.
November 1989, Blood,
G Meloni, and P De Fabritiis, and M C Petti, and A Pulsoni, and A Sandrelli, and A Covelli, and F Simone, and F Mandelli
High-dose chemotherapy with noncryopreserved autologous bone marrow transplantation for acute myeloid leukemia in first complete remission.
January 1990, Haematology and blood transfusion,
Copied contents to your clipboard!